Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: A randomized trial by the CIOP Study Group

Clinical Infectious Diseases

Volumn 36, Issue 5, 2003, Pages 645-651

  Mussini, Cristina ^a   Pezzotti, Patrizio ^d   Antinori, Andrea ^f   Borghi, Vanni ^a   D'Arminio Monforte, Antonella ^g   Govoni, Alessandra ^f   De Luca, Andrea ^e   Ammassari, Adriana ^e   Mongiardo, Nicola ^a   Cerri, Maria Chiara ^a   Bedini, Andrea ^a   Beltrami, Cristina ^h   Ursitti, Maria Alessandra ^c   Bini, Teresa ^g   Cossarizza, Andrea ^b   Esposito, Roberto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATOVAQUONE; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; INDINAVIR; LAMIVUDINE; MALOPRIM; PENTAMIDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CHEMOPREVENTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS;

EID: 0037371846     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367659     Document Type: Article

References (26)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30.
2. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
3. Schneider MME, Borleffs JCC, Stolk RP, Jaspers CAJJ, Hoepelman AIM. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353:201-3.
4. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1301-6.
5. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999; 353:1293-8.
6. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can prophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999; 13:1647-51.
7. Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. Ann Intern Med 2000; 132:201-5.
8. 3 during highly active antiretroviral therapy: the CIOP study. The CIOP Study Group. J Infect Dis 2000; 181:1635-42.
9. Lopez Bernaldo de Quiros JC, Miró JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med 2001; 344:159-67.
10. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001; 344:168-74.
11. Furrer H, Opravil M, Rossi M, et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS 2001; 15:501-7.
12. 6/L. AIDS 2001; 15:1509-15.
13. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177:1080-3.
14. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177:1182-7.
15. El Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of pro-phytaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342:1085-92.
16. + cell count: a randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133:493-503.
17. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy of disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002; 185:1179-82.
18. Martinez E, Garcia-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14:2615-7.
19. Meinert CL. Clinical trials: design, conduct, and analysis. Oxford, UK: Oxford University Press, 1986:95-6.
20. Montaner JS, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia: a randomized, placebo-controlled study. Ann Intern Med 1991; 114:948-53.
21. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodefidency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178:1126-32.
22. Vargas SL, Hughes WT, Wakefield AE, Oz HS. Limited persistence in and subsequent elimination of Pneumocystis carinii from the lungs after Pneumocystis carinii pneumonia. J Infect Dis 1995; 172:506-10.
23. Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun 1993; 61:5406-9.
24. Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis 1995; 172:595-8.
25. Tsolaki AG, Miller RF, Underwood AP, Banerji S, Wakefield AE. Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. J Infect Dis 1996; 174:141-56.
26. Abernathy-Carver KJ, Fan LL, Boguniewicz M, Larsen GL, Leung DY. Legionella and Pneumocystis pneumonias in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol 1994; 18:135-8.